


Incura

An innovative cure for all.

Developed by InCurA · Medical Devices · Hemostatics



THE PROBLEM

High-performance hemostats are costly and import-dependent

Controlling bleeding quickly and safely is critical across dental and surgical settings, yet the best-performing hemostatic products are expensive and largely imported. The region needed a locally developed, high-performance, low-cost alternative built on protectable IP.

THE SOLUTION

A pipeline of medical-device IP, made through licensing

InCurA develops high-performance, enhanced-efficacy medical devices with low-cost manufacturing, commercialized via license agreements. Its lead bleeding-control products are in partner manufacturing with Royah Pharmaceuticals in KSA, and its advanced wound-care line is licensed to industry partner Cigalah — the first hemostatic sponge line in MENA.

TECHNOLOGY · KEY SPECIFICATIONS

ColiSorB absorption	Up to 60x rapid blood absorption, no pre-wetting
ColiSorB pricing	USD 12–18 vs USD 20–27 for global comparators
CurASeal hemostasis	~1 minute time to hemostasis; 88 mg total blood loss
Biocompatibility	No cytotoxicity; complete body absorption under 4 days
Commercialization	License manufacturing with Royah Pharma and Cigalah (GCC & Levant)

IMPACT

01**Superior performance**

Delivering faster absorption and clotting than established global products.

02**Lower cost of care**

Pricing well below imported comparators while exceeding their performance.

03**Regional manufacturing**

Producing locally through license agreements across GCC and Levant.

04**Expanding pipeline**

Scaling from hemostatics into a multi-product advanced wound-care portfolio.